Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution Journal Article
| Authors: | Ryder, M.; Callahan, M.; Postow, M. A.; Wolchok, J.; Fagin, J. A. |
| Article Title: | Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution |
| Abstract: | Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis.We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8%and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology. © 2014 Society for Endocrinology. |
| Keywords: | advanced cancer; cancer risk; nonhuman; cancer incidence; disease association; ipilimumab; melanoma; image analysis; retrospective study; radiography; hypothyroidism; thyroid hormone; endocrine disease; hormone substitution; hypophysis hormone; hormone release; programmed death 1 receptor; medical history; hypophysitis; thyroiditis; adrenal disease; nivolumab; human; article; immune-related adverse effects |
| Journal Title: | Endocrine-Related Cancer |
| Volume: | 21 |
| Issue: | 2 |
| ISSN: | 1351-0088 |
| Publisher: | Bioscientifica Ltd |
| Date Published: | 2014-03-07 |
| Start Page: | 371 |
| End Page: | 381 |
| Language: | English |
| DOI: | 10.1530/erc-13-0499 |
| PROVIDER: | scopus |
| PUBMED: | 24610577 |
| PMCID: | PMC4573438 |
| DOI/URL: | |
| Notes: | Endocr.-Relat. Cancer -- Export Date: 2 June 2014 -- CODEN: ERCAE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work